Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026

Core Insights - Saira Ramasastry, a director at Mirum Pharmaceuticals, executed the exercise of 5,000 stock options and sold the resulting shares for a total transaction value of $400,000 on December 22 [2][7]. Transaction Summary - The transaction involved the direct sale of 5,000 shares, with a total value of $400,000, based on a weighted average purchase price of $80.00 per share [3]. - Post-transaction, Ramasastry holds no direct common shares, as the entire transaction accounted for 100% of her direct holdings [8]. Company Overview - Mirum Pharmaceuticals reported a revenue of $471.79 million and a net income of -$41.42 million for the trailing twelve months (TTM) [5]. - The company's stock price increased by 90.71% over the past year, calculated using December 22 as the reference date [5]. Company Snapshot - Mirum specializes in developing therapies for rare and orphan liver diseases, with its lead product being LIVMARLI and additional candidates like Volixibat in its pipeline [6]. Operational Performance - Preliminary results for 2025 indicate net product sales of approximately $520 million, exceeding guidance, with forecasts of $630 million to $650 million in global net product sales for 2026 [11]. - The company ended 2025 with an estimated $392 million in cash and investments and achieved positive operating cash flow, allowing for pipeline expansion and the proposed acquisition of Bluejay Therapeutics [11].